Commissioning & High Cost Drugs: Quality & Cost Effective Prescribing within the ICS

These meetings are intended for UK Healthcare Professionals and have been developed in accordance with the ABPI Code of Practice.

PM Healthcare events are Quality Assured by the University of Bradford 

     

Event Name Commissioning & High Cost Drugs: Quality & Cost Effective Prescribing within the ICS
Location Royal College of General Practitioners, 30 Euston Square, London, NW1 2FB
Start Date 8:45am 28/02/2024
Finish Date 4:00pm 28/02/2024
Booking Closes 4:00pm 27/02/2024 - Closing Soon!
Places Available
Event Description

The conference will be aimed at High Cost Medicines Optimisation Pharmacists, GP Clinical Pharmacists, Commissioning Pharmacists, Medicines Optimisation Managers, Chief Pharmacists and other Pharmacists from across Primary Care Networks and Integrated Care Boards. Additionally Chief Pharmacists, Specialist Clinical Pharmacists and other Secondary Care Pharmacists as well as Pharmacy Technicians.

Session Synopses:

The Changing Landscape of High Cost Drugs

Stephen Cook - Chief Pharmacist, Medway NHS Foundation Trust

Medicines are often cited as the highest non-pay expenditure in the NHS today; comprising of low cost high volume predominantly primary care prescribing, and high cost low volume interventions that are separately commissioned for delivery through secondary and specialist care settings.

This session will set the scene by considering the current and future landscape for commissioning, management and delivery of high cost drugs in evolving healthcare systems.

 

The ICS Model for Medicines Optimisation

Vanessa Burgess - Chief Pharmacist, South East London Integrated Care Board

High-Cost Drugs (HCDs) are medicines excluded from the national prices and unit price calculations. HCDs are funded in line with a NICE TA or commissioning policy in England by Specialised commissioning or Integrated Care Boards (ICBs) as identified in the NHS England Prescribed Specialised Services Manual. Unlike specialised commissioned treatments, there is no centralised commissioning or assurance process for ICB commissioned HCDs following a NICE appraisal. This has led to variation in approaches to the management and assurance of high-cost medicines by ICBs. This session will invite views on potential collaborations between ICBs to reduce variation and consider approaches which focus on improving patient pathways and outcomes with minimal focus on bureaucracy.

 

Navigating Health Inequalities: An Experiential Approach

Dr Dawn Price - Managing Director, Mistura Informatics Ltd

Stark disparities exist between the health access and outcomes experienced by the population of the UK evidenced by a stalling in life expectancy (and related measures of public health) whereas, in other high-income countries, it continues to rise. The priorities for the NHS long-term Plan therefore are to target these health Inequalities both “at pace” and “at scale”.

This session focuses on the background of health inequalities and the issues to be aware of, highlights the priorities and outcomes that can be measured, and discusses the opportunities and challenges for Pharmacies in adopting these concepts.

 

Developing New Systems

Mohammed Asghar - Associate Director of Pharmacy: Prescribing Governance, Frimley Health and Care ICS

With the advent of ICBs taking statutory responsibility for population health across systems, what new mechanisms and structures for oversight are needed and being developed within ICS’s? How have these impacted on how we undertake Medicines Optimisation? Where are we currently and what can we learn from the journey to get here; the journey isn't complete, so where do we need to get to and what will help us get there? How will Pharmacy play a greater role within these new systems to better achieve Medicines Optimisation?

 

In a world of change and pressure, how can we become more resilient?

Ivan Hollingsworth - Director, Centric Consultants Limited

Increasingly in modern-day society, certain words seem to have been misappropriated by either the ill-informed or those who seek to exert power over others; resilience is one of these words.

This session will aim to detoxify, de-weaponise and break the myths around resilience; through understanding it is not an attribute or characteristic you are born with, rather an output of your mindset, behaviours, and environment.

Walk through the 6 pillars of resilience and build strategies that can help you to become better able to deal with life’s challenges and adversities.

 

Inequality in Access to Medicines

Rena Amin - Associate Director, Learning Disability & Autism Programme, Stomp/Stamp Lead, South East London Integrated Care Board

The session will cover inequalities in access to medicines in primary care in relation to Learning Disability and Autism (LDA). People with LDA have poor quality access to healthcare which causes inequalities and premature death. This session will focus on measures that can be taken in primary care, through a sustainable multi-disciplinary programme to improve diagnostic validation, consideration of prescribing decisions and meaningful annual health checks within the local health economy. Providing structured training to the workforce improves the much-needed capacity in primary care but enables improvement in access to healthcare. This session will also include the importance of engagement with carers and harnessing their expertise for future service developments.

 

A Vision for Pharmacy Professional Practice in England: One Year On

Tase Oputu - Associate Director of Medicines Optimisation - High Cost Drugs, NHS Kent & Medway; Chair - English Pharmacy Board, Royal Pharmaceutical Society

In collaboration with The King’s Fund, the Royal Pharmaceutical Society in England published a Vision for Pharmacy Professional practice in England in December 2022. The vision scope was to examine the future of pharmacy professional practice and development, and how the health and care system in England can maximise the support pharmacy teams provide to patients and the public. The 10-year vision spans the hospital sector, general practice, community pharmacy, commissioning and leadership, industry and academia and recognises the many opportunities for pharmacy teams to provide better support to patients and the public to prevent ill health, improve health and reduce health inequalities.
 
This session will look at progress made in the 12 months since the publication, highlighting changes in practice and developments in 2023.

 

Collaborative Working

Andrew Walker - Oncology Pharmacist/Clinical Leadership Fellow, Yorkshire and Humberside Future Leaders Programme

This session will discuss an ongoing pilot project investigating the role of community and primary care pharmacy professionals supporting the early identification of patients with symptoms of lung cancer across Leeds. This session will cover the initial project development through to implementation, sharing experiences of effective cross sector collaboration between an ICB cancer programme, community pharmacy providers and secondary care radiology services to deliver a project to help address health inequalities and improve patient access to diagnostic services. 

 

Treatment Pathways: What are the early opportunities for success and how to deliver?

Rebecca Aderinola & Thelma Okunuga - Lead Medicines Management Pharmacists: High Cost Drugs, NHS Kent and Medway

This session will provide valuable insights into the early opportunities for success and effective strategies for delivering optimal outcomes specifically through the development of regional clinical treatment pathways. We will explore how collaboration and engagement with stakeholders are crucial elements in creating these pathways, showcasing the journey and timelines involved. Lessons learned, benefits, challenges and the importance of using various communication channels in the success of these pathways will be discussed. In the session we will also demonstrate the pathway designs, with specific emphasis on the unique considerations to high-cost drugs.

 

Regional Commissioning Teams & IMOCs

Ewan Maule - Director of Medicines and Pharmacy, North East and North Cumbria ICB

Integrated Medicines Optimisation Committees (IMOCs) or other similarly titled structures have a vital role to play in ICB and ICS governance, strategy and decision making. This session will explore some of the challenges and opportunities facing IMOCs in the new environment and consider how high cost drugs are and can be managed within this.

 

Homecare: Current Challenges. Is the Model “Fit for Purpose”?

Geoffrey Howell - Principal Pharmacist: Clinical Commissioning & Medicines Finance, King's College Hospital NHS Foundation Trust

The presentation will explore the challenges faced in delivering homecare services at Kings College Hospital NHS Foundation Trust (KCH), London, exploring their impact on both operational efficiency and patient care. These challenges will be connected to the insights from the House of Lords inquiry, highlighting the necessary support required for the homecare sector. Additionally, we will discuss some of the ongoing projects at KCH aimed to enhance homecare services.

 

Pharmacogenomics

Dharmisha Chauhan - Lead Genomic Pharmacist, North Thames Genomic Medicine Service Alliance hosted by Great Ormond Street Hospital

Pharmacogenetics is routinely used within clinical practice in cancer care and some centres are using pharmacogenetics to prevent drug-induced hearing loss. Cardiovascular medicines is now beginning to implement CYP2C19 testing into clinical pathways and interest within mental health care is growing. The aim of this presentation is to provide an understanding of what pharmacogenetics is and how it can be mainstreamed into routine clinical care across all healthcare settings.

 

Shared Care

Jagjot Chahal - Cardiovascular Disease Prevention Lead Pharmacist, Barts Health NHS Trust

This session showcases an example of a multi-organisational collaboration to address the national cardiovascular disease (CVD) prevention agenda and the unmet need of the local population of North-East London. 

A novel integrated pathway was developed, involving specialist input from a multidisciplinary team where specialist hospital pharmacists work directly with primary care teams, across traditional organisational boundaries. This entailed identifying people with or at risk of CVD; optimising preventative medication usage, improving access to new therapies; and treating patients closer to home without the need for onward referral to hospital.

 

Funding & Budgets

Mohammed Asghar - Associate Director of Pharmacy: Prescribing Governance, Frimley Health and Care ICS

How is finance allocated for Medicines within the ICS world, what are the opportunities arising from working to a system financial envelope and the transfer of finances, not just between the primary and secondary care interface, but also between different work stream budgets? How could these changes affect the way Pharmacy and Medicines Optimisation teams work in future?

 

What is health economics and how does it influence the way we use medicines?

Melinda Goodall - Health Technology Assessment (HTA) Policy Consultant, Goodall HTA Consulting Ltd

The session will introduce the concepts and application of health economics in the NHS. It will discuss how health economics is used at The National Institute for Health and Care Excellence (NICE) to make decisions on access to new medicines, and to inform the development of NICE treatment Guidelines. The session will reflect on what we see now and what we can expect in the future.

 

Creating a Business Case for the Modern NHS

Matthew Harrison - Head of Pharmacy, HCA Healthcare UK

Matt will walk through what he sees as necessary to be successful in a pharmacy business case, how to present this to people who make the decisions and how to show every ounce of value gained using technology and data for the modern NHS. He will also go through some of his past mistakes (and how to avoid them!) and some basic financial analysis models.

 

Best Value Medicines

James Hartwell - Lead Pharmacist: Performance, Formulary and Medicines Value, Dartford & Gravesham NHS Trust

Best Value Medicines will explore various ways of assigning “value” to medicines. Firstly exploring what value can be derived from each medicine, how they can be revenue generation and also exploring more sustainable use of medicines through some of the initiatives.

 

This event will be funded by the following companies through event sponsorship, sponsored satellite sessions and stand sponsorship. These companies have had no input into the design or content of the conference agenda (other than their own sessions) but will be in attendance on the day.

Headline Sponsor: Bayer plc

Stand Sponsors: AbbVie, AstraZeneca, Fresenius Kabi Ltd, LEO Pharma UK/IE, Lupin Healthcare, Pfizer Ltd, Spirit Healthcare, Teva UK

 

Agenda Download Agenda PDF
Contact Name Client Services
More Details Email for more details.
Your booking is always provisional until we confirm it!
Login Create Account

Satellites for this Event

The ICS Model for Medicines Optimisation

Speakers: Vanessa Burgess - Chief Pharmacist, South East London Integrated Care Board

Session Synopsis:

High-Cost Drugs (HCDs) are medicines excluded from the national prices and unit price calculations. HCDs are funded in line with a NICE TA or commiss...

Read more »

Navigating Health Inequalities: An Experiential Approach

Speakers: Dr Dawn Price - Managing Director, Mistura Informatics Ltd

Session Synopsis:

Stark disparities exist between the health access and outcomes experienced by the population of the UK evidenced by a stalling in life expectancy (an...

Read more »

Developing New Systems

Speakers: Mohammed Asghar - Associate Director of Pharmacy:Prescribing Governance, Frimley Health and Care ICS

Session Synopsis:

With the advent of ICBs taking statutory responsibility for population health across systems, what new mechanisms and structures for oversight are ne...

Read more »

In a world of change and pressure, how can we become more resilient?

Speakers: Ivan Hollingsworth - Director, Centric Consultants Limited

Session Synopsis:

Increasingly in modern-day society, certain words seem to have been misappropriated by either the ill-informed or those who seek to exert power over ...

Read more »

Inequality in Access to Medicines

Speakers: Rena Amin - Associate Director, Learning Disability & Autism Programme, Stomp/Stamp Lead, South East London Integrated Care Board

Session Synopsis:

The session will cover inequalities in access to medicines in primary care in relation to Learning Disability and Autism (LDA). People with LDA have ...

Read more »

A Vision for Pharmacy Professional Practice in England: One Year On

Speakers: Tase Oputu - Associate Director of Medicines Optimisation - High Cost Drugs, NHS Kent & Medway; Chair - English Pharmacy Board, Royal Pharmaceutical Society

Session Synopsis:

In collaboration with The King’s Fund, the Royal Pharmaceutical Society in England published a Vision for Pharmacy Professional practice in Eng...

Read more »

Collaborative Working

Speakers: Andrew Walker - Oncology Pharmacist/Clinical Leadership Fellow, Yorkshire and Humberside Future Leaders Programme

Session Synopsis:

This session will discuss an ongoing pilot project investigating the role of community and primary care pharmacy professionals supporting the early i...

Read more »

Treatment Pathways: What are the early opportunities for success and how to deliver?

Speakers: Rebecca Aderinola & Thelma Okunuga - Lead Medicines Management Pharmacists – High Cost Drugs, NHS Kent and Medway

Session Synopsis:

This session will provide valuable insights into the early opportunities for success and effective strategies for delivering optimal outcomes specifi...

Read more »

Regional Commissioning Teams & IMOCs

Speakers: Ewan Maule - Director of Medicines and Pharmacy, North East and North Cumbria ICB

Session Synopsis:

Integrated Medicines Optimisation Committees (IMOCs) or other similarly titled structures have a vital role to play in ICB and ICS governance, strate...

Read more »

Pharmacogenomics

Speakers: Dharmisha Chauhan - Lead Genomic Pharmacist, North Thames Genomic Medicine Service Alliance hosted by Great Ormond Street Hospital

Session Synopsis:

Pharmacogenetics is routinely used within clinical practice in cancer care and some centres are using pharmacogenetics to prevent drug-induced hearin...

Read more »

Shared Care

Speakers: Jagjot Chahal - Cardiovascular Disease Prevention Lead Pharmacist, Barts Health NHS Trust

Session Synopsis:

This session showcases an example of a multi-organisational collaboration to address the national cardiovascular disease (CVD) prevention agenda and ...

Read more »

Funding & Budgets

Speakers: Mohammed Asghar - Associate Director of Pharmacy: Prescribing Governance, Frimley Health and Care ICS

Session Synopsis:

How is finance allocated for Medicines within the ICS world, what are the opportunities arising from working to a system financial envelope and the t...

Read more »

What is health economics and how does it influence the way we use medicines?

Speakers: Melinda Goodall - Health Technology Assessment (HTA) Policy Consultant, Goodall HTA Consulting Ltd

Session Synopsis:

The session will introduce the concepts and application of health economics in the NHS. It will discuss how health economics is used at The National ...

Read more »

Best Value Medicines

Speakers: James Hartwell - Lead Pharmacist - Performance, Formulary and Medicines Value, Dartford & Gravesham NHS Trust

Session Synopsis:

Best Value Medicines will explore various ways of assigning “value” to medicines. Firstly exploring what value can be derived from each m...

Read more »

Website by MAXX Design

© 2024 Pharman | All rights reserved | Site Map | Accessibility | Privacy and Cookie Policy | Terms & Conditions

Confirmation

This site is intended for healthcare professionals or people employed in the pharmaceutical industry. Please confirm that you are such a person.

Continue